Current Report Filing (8-k)
April 21 2015 - 9:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 21, 2015
ONCOTHYREON INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-33882 |
|
26-0868560 |
(State or other jurisdiction of
incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
2601 Fourth Avenue, Suite 500
Seattle, Washington 98121
(Address of principal executive offices, including zip code)
(206) 801-2100
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
Dr. Jay Venkatesan notified Oncothyreon Inc. (the Company) of his intention to resign as the Executive Vice President and General Manager of
the Company, effective May 15, 2015, to accept a position as Chief Executive Officer of a private biotechnology company. In connection with his resignation from the Company, Dr. Venkatesan entered into a lock-up agreement with the Company
that prohibits him from selling, pledging, assigning or otherwise transferring any shares beneficially owned by him for 180 days after his resignation, subject to certain exceptions.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
ONCOTHYREON INC. |
|
|
By: |
|
/s/ Robert L. Kirkman |
|
|
Robert L. Kirkman |
|
|
President & Chief Executive Officer |
Date: April 21, 2015
3
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Sep 2023 to Sep 2024